Last checked at 17 Jul 2018 13:12
N4 Pharma Plc
("N4 Pharma" or the "Company")
Holdings in Company
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, announces that it was notified on 16 July 2018 that Mr David Farrier, an existing Substantial Shareholder in the Company (as defined in the AIM Rules for Companies), is beneficially interested in 11,675,366 ordinary shares of 0.4 pence each, representing 12.8 per cent. of the Company's issued share capital.
Enquiries:
N4 Pharma Plc Nigel Theobald, CEO |
Via Alma PR
|
Stockdale Securities Tom Griffiths / David Coaten
| Tel: +44(0)207 601 6100 |
Alma PR Josh Royston Robyn Fisher |
Tel: +44(0)778 090 1979 Tel: +44(0)754 070 6191 |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance.
N4 Pharma's reformulation work falls under two divisions:
· generic, already commercialised, drugs; and
· novel delivery system for nucleic acids.
N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.
N4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model for generics is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma's revenues should be derived from up front milestone and royalty payments associated with the licence.
N4 Pharma's business model for Nuvec® nanoparticles is to undertake the required pre-clinical work to demonstrate the capability of its nucleic acid delivery system as part of a vaccine and/or method to deliver DNA/RNA so that it can license the technology to major players developing treatments in this area, again in return for up front milestone and royalty payments associated with the licence.